Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial

Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer. METHODS: The Finland Capecitabine Trial (FinXX) is a randomized, open-label, multicenter trial that evaluates integration of capecitabine to an adjuvant chemotherapy re...

Descripción completa

Detalles Bibliográficos
Autores principales: Joensuu, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Huovinen, Riikka, Jukkola, Arja, Tanner, Minna, Ahlgren, Johan, Auvinen, Päivi, Lahdenperä, Outi, Villman, Kenneth, Nyandoto, Paul, Nilsson, Greger, Poikonen-Saksela, Paula, Kataja, Vesa, Bono, Petri, Junnila, Jouni, Lindman, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966968/
https://www.ncbi.nlm.nih.gov/pubmed/35020465
http://dx.doi.org/10.1200/JCO.21.02054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966968/
https://www.ncbi.nlm.nih.gov/pubmed/35020465
http://dx.doi.org/10.1200/JCO.21.02054

Ejemplares similares